Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Share Embed Flag
Download ePaper

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

(2001): Robinson JB+, Gynecol Oncol 82(3), 550 (with carboplatin) (2001): Szebeni J+, Int Immunopharmacol 1(4), 721 (2001): Yamada Y+, Ann Oncol 12(8), 1133 (15%) (1998): Borovik R+, Harefuah (Hebrew) 134, 605 (1998): Lokich J+, Ann Oncol 9, 573 (1998): Tsavaris NB+, Cancer Chemother Pharmacol 42, 509 (1995): Del Priore G+, Gynecol Oncol 56, 316 (1994): Uziely B+, Ann Oncol 5, 474 (1993): Peereboom DM+, J Clin Oncol 11, 885 Inappropriate secretion of antidiuretic hormone (SIADH) (2005): Yokoyama Y+, Eur J Gynaecol Oncol 26(5), 531 Infections (sic) (3–22%) (2006): Yamamoto N+, Anticancer Res 26(1B), 777 (2003): Formenti SC+, J Clin Oncol 21(5), 864 (22%) (2003): Kuhnt T+, Strahlenther Onkol 179(10), 673 (2002): Souglakos J+, Cancer 95(6), 1326 (3%) (2001): Fidias P+, Clin Cancer Res 7(12), 3942 (8.8%) Injection-site cellulitis (>10%) Injection-site extravasation (>10%) (2002): Barutca S+, Support Care Cancer 10(7), 563 (1997): Herrington JD+, Pharmacotherapy 17, 163 (1995): Berghmans T+, Support Care Cancer 3, 203 (1995): Raymond E+, Rev Med Interne (French) 16, 141 Injection-site pain (>10%) Injection-site reactions (sic) (13%) (2003): Leyland-Jones B+, J Clin Oncol 21(21), 3965 (with trastuzumab) Myalgia/Myositis/Myopathy/Myotoxicity (19–60%) (2006): Izquierdo MA+, Eur J Cancer 42(12), 1789 (with docetaxel) (2005): Ansari TN+, J Coll Physicians Surg Pak 15(4), 200 (2003): Garrison JA+, Oncology (Huntingt) 17(2), 271 (2003): Leyland-Jones B+, J Clin Oncol 21(21), 3965 (with trastuzumab) (2002): Cantu MG+, J Clin Oncol 20(5), 1232 (19%) (2002): Hasegawa K+, Gan To Kagaku Ryoho 29(4), 569 (2001): Ishikawa H+, Int J Clin Oncol 6(3), 128 (1999): Markman M+, Gynecol Oncol 72, 100 (1999): Villalona-Calero MA+, J Clin Oncol 17(6), 1915 (with capecitabine) (1998): Savarese D+, J Clin Oncol 16, 3918 (1997): Jiang Z+, Chung Hua Chung Liu Tsa Chih (Chinese) 19, 445 Nephrotoxicity (2006): Ozguroglu M+, Int J Gynecol Cancer 16 Suppl 1, 394 (with carboplatin) Neurotoxicity (2006): Bamias A+, BMC Cancer 6, 228 (with carboplatin) (2006): Bell J+, Gynecol Oncol 102(3), 432 (with carboplatin) (2006): Green MR+, Ann Oncol 17(8), 1263 (2006): Izquierdo MA+, Eur J Cancer 42(12), 1789 (with docetaxel) (2006): Koizumi W+, Anticancer Res 26(5B), 3797 (2006): Lachkar S+, Rev Mal Respir 23(1 Pt 1), 73 (2006): Le T+, Gynecol Oncol 102(1), 49 (15%) (2006): Markman M+, Gynecol Oncol 101(3), 436 (21%) (2006): Melli G+, Neurobiol Dis 24(3), 525 (2006): Yamamoto N+, Anticancer Res 26(1B), 777 (2005): Kahl BS+, Cancer Invest 23(1), 13 Pain (2006): Blum JL+, J Clin Oncol 24(27), 4384 (with capecitabine) (2003): Emoto T+, Gan To Kagaku Ryoho 30(6), 809 (2003): Formenti SC+, J Clin Oncol 21(5), 864 (17%) Thrombosis (2006): Feres F+, Catheter Cardiovasc Interv 68(1), 83 (stent) Tumor lysis syndrome (2006): Yahata T+, Gynecol Oncol 103(2), 752 PALIFERMIN Trade name: Kepivance (Amgen) Indications: Severe oral mucositis in cancer patients Category: Keratinocyte growth factor Half-life: 4.5 hours Clinically important, potentially hazardous interactions with: heparin Reactions Skin Edema (2006): Blazar BR+, Blood 108(9), 3216 Erythema (32%) (2004): Spielberger R+, NEnglJMed351(25), 2590 Pruritus (35%) (2004): Spielberger R+, NEnglJMed351(25), 2590 Rash (sic) (62%) (2006): Blazar BR+, Blood 108(9), 3216 (2006): Keefe D+, Support Care Cancer 14(6), 580 (2004): Spielberger R+, NEnglJMed351(25), 2590 Toxicity (sic) (2005): Siddiqui MA+, Drugs 65(15), 2139 Mucosal Gingival hyperplasia/hypertrophy (2001): Das SJ+, JPeriodontol72(6), 745 Oral mucositis (2006): Keefe D+, Support Care Cancer 14(6), 580 Tongue edema (17%) (2004): Spielberger R+, NEnglJMed351(25), 2590 Tongue pigmentation (17%) Other Fever (39%) Infections (2006): Blazar BR+, Blood 108(9), 3216 Pain (16%) (2006): Blazar BR+, Blood 108(9), 3216 PALIPERIDONE Trade name: Invega (Janssen) Indications: Schizophrenia Half-life: ~23 hours Clinically important, potentially hazardous interactions with: N/A Note: Paliperidone is the active metabolite of risperidone Reactions Skin Angioedema (tongue) Edema Other Abdominal pain Anaphylactoid reactions/Anaphylaxis PALIPERIDONE 413

414 PALIVIZUMAB PALIVIZUMAB Trade name: Synagis (MedImmune) Indications: Prophylaxis of serious lower respiratory tract disease caused by RSV in pediatric patients Category: Immunomodulator; Monoclonal antibody Half-life: 18 days Reactions Skin Eczema (>1%) Erythema Fungal dermatitis (>1%) Rash (sic) (25.6%) Seborrhea (>1%) Mucosal Oral candidiasis (>1%) Other Anaphylactoid reactions/Anaphylaxis (2002): Medscape Medical News Fever (2004): Fenton C+, Paediatr Drugs 6(3), 177 Infections Injection-site bruising (1–3%) (1999): Scott LJ+, Drugs 58, 305 (1–3%) Injection-site edema (1–3%) (1999): Scott LJ+, Drugs 58, 305 (1–3%) Injection-site erythema (1–3%) (1999): Scott LJ+, Drugs 58, 305 (1–3%) (1998): Pediatrics 102, 531 Injection-site induration (1–3%) (1999): Scott LJ+, Drugs 58, 305 (1–3%) Injection-site pain (1–8.5%) (1999): Scott LJ+, Drugs 58, 305 (1–3%) Injection-site reactions (sic) (2004): Fenton C+, Paediatr Drugs 6(3), 177 (1999): Sandritter T, J Pediatr Health Care 13, 191 PALONOSETRON Trade names: Aloxi (MGI); Onicit Indications: Antiemetic (for cancer chemotherapy) Category: 5-HT3 antagonist; Serotonin type 3 receptor antagonist Half-life: 40 hours Reactions Skin Dermatitis (

414 PALIVIZUMAB<br />

PALIVIZUMAB<br />

Trade name: Synagis (MedImmune)<br />

Indications: Prophylaxis of serious lower respiratory tract<br />

disease caused by RSV in pediatric patients<br />

Category: Immunomodulator; Monoclonal antibody<br />

Half-life: 18 days<br />

Reactions<br />

Skin<br />

Eczema (>1%)<br />

Erythema<br />

Fungal dermatitis (>1%)<br />

Rash (sic) (25.6%)<br />

Seborrhea (>1%)<br />

Mucosal<br />

Oral c<strong>and</strong>idiasis (>1%)<br />

Other<br />

Anaphylactoid reactions/Anaphylaxis<br />

(2002): Medscape Medical News<br />

Fever<br />

(2004): Fenton C+, Paediatr <strong>Drug</strong>s 6(3), 177<br />

Infections<br />

Injection-site bruising (1–3%)<br />

(1999): Scott LJ+, <strong>Drug</strong>s 58, 305 (1–3%)<br />

Injection-site edema (1–3%)<br />

(1999): Scott LJ+, <strong>Drug</strong>s 58, 305 (1–3%)<br />

Injection-site erythema (1–3%)<br />

(1999): Scott LJ+, <strong>Drug</strong>s 58, 305 (1–3%)<br />

(1998): Pediatrics 102, 531<br />

Injection-site induration (1–3%)<br />

(1999): Scott LJ+, <strong>Drug</strong>s 58, 305 (1–3%)<br />

Injection-site pain (1–8.5%)<br />

(1999): Scott LJ+, <strong>Drug</strong>s 58, 305 (1–3%)<br />

Injection-site reactions (sic)<br />

(2004): Fenton C+, Paediatr <strong>Drug</strong>s 6(3), 177<br />

(1999): S<strong>and</strong>ritter T, J Pediatr Health Care 13, 191<br />

PALONOSETRON<br />

Trade names: Aloxi (MGI); Onicit<br />

Indications: Antiemetic (for cancer chemotherapy)<br />

Category: 5-HT3 antagonist; Serotonin type 3 receptor<br />

antagonist<br />

Half-life: 40 hours<br />

Reactions<br />

Skin<br />

Dermatitis (

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!